The dual role of NMDA receptors in the normal and abnormal functioning of the nervous system imposes important constraints on possible therapeutic strategies aimed at ameliorating ro abating developmental disorders and neurological disease. Based on our groups previous work, two groups of drugs are likely to show promise for safe but effective pharmacological intervention to curtail excessive activity of the NMDA receptor: (i) memantine, a use-dependent and uncompetitive antagonist that is an NMDA open-channel blocker, and (ii) nitric oxide (NO)-related species (provided by nitroglycerin) that interact with redox modulatory sites on the NMDA receptor. In our preliminary results, we have demonstrated the following: 1) the glutamine/arginine/asparagine (Q/R/N) sites in the second membrane spanning (M2) domains of NMDAR1 and NMDAR2 subunits strongly affect memantine binding; 2) there exist three kinetically-distinct components of redox modulation on NR1a/NR2A heteromeric channels that are affected by redox agents; 3) each kinetic NR2A component or redox modulation can be attributed to interaction with a pair of cysteine residues on the NR1 or NR2A subunits and these subunits also affect modulation by Zn; 4) one cysteine residue on NR2A is predominantly responsible for modulation of the NMDAR activity by NO-related species. Furthermore, we recently isolated a novel NMDAR subunit, NR3A (previously designated NMDAR-L or khi-1), from the rat CNS. Co-expression of NR1/nr2a OR b/nr3a IN Xenopus oocytes decreases unitary conductance in single-channel recordings. Conversely, NR3A-deficient mice have larger than normal NMDA-evoked currents. The new project will further study these knock-out mice. We also obtained a near full-length cDNA clone of a second novel NMDAR subunit, tentatively named NR3B since it shows high sequence identify to NR3A. We propose: [1] To study the structural determinants of memantine binding in the channel pore of the NMDAR, [2] To characterize the cysteine residues underlying redox, Zn, and No modulation of the NMDAR, [3] To elucidate the molecular mechanism of action of NR3A whereby it decreases NMDAR-activated current. [4] To clone and characterize a second novel NMDAR subunit, NR3B, in order to determine the function role that it subserves in the developing brain. Most importantly, drugs developed in Project will be used for neuroprotection from hypoxic-ischemic injury and AIDS-related neuronal damage.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
2P01HD029587-07A1
Application #
6208017
Study Section
Special Emphasis Panel (ZHD1-MRG-C (SL))
Project Start
1992-09-01
Project End
2004-08-31
Budget Start
Budget End
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
009214214
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Mann, Aman P; Scodeller, Pablo; Hussain, Sazid et al. (2018) Publisher Correction: Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nat Commun 9:1070
Nagar, Saumya; Noveral, Sarah M; Trudler, Dorit et al. (2017) MEF2D haploinsufficiency downregulates the NRF2 pathway and renders photoreceptors susceptible to light-induced oxidative stress. Proc Natl Acad Sci U S A 114:E4048-E4056
Mann, Aman P; Scodeller, Pablo; Hussain, Sazid et al. (2017) Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nat Commun 8:1403
Tu, Shichun; Akhtar, Mohd Waseem; Escorihuela, Rosa Maria et al. (2017) NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism. Nat Commun 8:1488
Satoh, Takumi; Lipton, Stuart (2017) Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000Res 6:2138
Nakamura, Tomohiro; Lipton, Stuart A (2017) 'SNO'-Storms Compromise Protein Activity and Mitochondrial Metabolism in Neurodegenerative Disorders. Trends Endocrinol Metab 28:879-892
Chen, Shanyan; Cui, Jiankun; Jiang, Tao et al. (2017) Gelatinase activity imaged by activatable cell-penetrating peptides in cell-based and in vivo models of stroke. J Cereb Blood Flow Metab 37:188-200
Nagar, Saumya; Trudler, Dorit; McKercher, Scott R et al. (2017) Molecular Pathway to Protection From Age-Dependent Photoreceptor Degeneration in Mef2 Deficiency. Invest Ophthalmol Vis Sci 58:3741-3749
Eichmann, Cédric; Tzitzilonis, Christos; Nakamura, Tomohiro et al. (2016) S-Nitrosylation Induces Structural and Dynamical Changes in a Rhodanese Family Protein. J Mol Biol 428:3737-51
Akhtar, Mohd Waseem; Sanz-Blasco, Sara; Dolatabadi, Nima et al. (2016) Elevated glucose and oligomeric ?-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation. Nat Commun 7:10242

Showing the most recent 10 out of 175 publications